Form 4: Bionano General Counsel Granted Stock Options

Bionano Genomics' General Counsel, Jonathan V. Dixon, was granted 26,117 stock options with an exercise price of $1.27, vesting over four years.

Summary

• Jonathan V. Dixon, General Counsel of Bionano Genomics, Inc. (BNGO), acquired 26,117 derivative securities in the form of stock options.
• The stock options have an exercise price of $1.27 per share.
• The options were granted on February 2, 2026, which is also the vesting commencement date.
• Each option award vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date.
• The options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.
• The expiration date for these stock options is February 1, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development. While a routine compensation event, it signifies continued executive alignment with company performance, which is generally favorable for corporate governance and long-term strategy.

Positives

• The grant of stock options aligns the interests of the General Counsel with those of shareholders, incentivizing long-term company performance.
• This is a standard form of executive compensation, indicating ongoing commitment to key management personnel.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule and expiration date of the granted options.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like the General Counsel is a common practice across the biotechnology and life sciences industries. This compensation structure is designed to retain talent and align management incentives with long-term shareholder value creation, a strategy widely adopted by companies similar to Bionano Genomics.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, are standard practice in the biotechnology sector, often used by companies like Illumina, Pacific Biosciences, and Oxford Nanopore Technologies to attract and retain top talent.
• The vesting schedule of 48 months is typical for executive stock options, promoting long-term commitment, comparable to grants observed at peer companies in the genomics and diagnostics space.

Stakeholder Impact

• Shareholders: The grant of options aims to align management's interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: This compensation structure is typical for executive roles, potentially signaling stability in the executive team.

Next Steps

• The stock options will vest monthly over the next 48 months, with full vesting occurring on the four-year anniversary of the grant date (February 2, 2030).
• The General Counsel may exercise vested options at any time before the expiration date of February 1, 2036.

Key Dates

Keywords

Bionano Genomics, BNGO, stock options, insider transaction, Form 4, Jonathan V. Dixon, General Counsel, executive compensation